A multicenter prospective observational study on the structured parenteral opioid intervention for dyspnea in terminally-ill cancer patients

A multicenter prospective observational study on the structured parenteral opioid intervention for dyspnea in terminally-ill cancer patients - A multicenter prospective observational study on the structured parenteral opioid intervention for dyspnea in terminally-ill cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039147

Enrollment

100

Registered

2020-01-20

Start date

2020-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hospitalized patients with the age of 18 or greater 2) Patients diagnosed with locally advanced or metastatic cancer 3) Patients started on the continuous administration of parenteral opioids for dyspnea (IPOS/STAS of 2 or greater) 4) Patients receiving care by palliative care specialist(s) at a palliative care unit or palliative care team 5) ECOG Performance Status 3 or 4 6) Communication Capacity Scale (CCS), item 4 of 2 or lower

Exclusion criteria

Exclusion criteria: 1) Patients who will receive treatent for dyspnea that clearly has no direct pathophysiological association with cancer 2) Patients who are planning to undergo interventions that would change symptom intensity during a short period within 3 days. 3) Patient or family decline to participation

Design outcomes

Primary

Measure	Time frame
The percentage of patients who receive a structured parenteral opioid intervention at 24 (18-30) hours after the initiation of the intervention for dyspnea	—

Secondary

Measure	Time frame
The percentage of the utilization of a structured parenteral opioid intervention, achievement of treatment goals, contents of concurrent treatment such as increase and/or switching of opioids and benzodiazepines, dyspnea intensity, communication capacity and consciousness level, adverse events and dose-limiting toxicities, etc.	—

Countries

Japan

Contacts

Public ContactMasanori Mori

Seirei Mikatahara General Hospital Palliative and Supportive Care Division

masanori.mori@sis.seirei.or.jp0534361251

Outcome results